We aimed to determine the optimum timing of midazolam administration prior to propofol to achieve the maximal reduction in the dose of propofol required to induce anaesthesia. Female (ASA 1-2) patients, aged 18 to 45 years, weighing 40 to 75 kg and scheduled for gynaecological surgery were eligible for the study. Consenting patients were randomly assigned to six groups. Group 1 received saline and Groups 2 to 6 received midazolam 3 mg at 1, 2, 4, 6 or 10 minutes respectively prior to propofol (n=20 to 22 per group) in a blinded manner. Propofol was administered IV over 10 seconds and flushed in with saline 5 ml. Two minutes later, the patient's response to pressure applied to the finger was determined as an index of loss of consciousness. The ED50 of propofol in each group was determined by the up-and-down method. Propofol ED50 was reduced to 34 to 67% (P<0.001) in the midazolam treated groups. There was no significant (P=0.14) difference in propofol ED50 among the five groups which received midazolam. Patients who received midazolam had less recollection of events surrounding induction (P<0.001) and recalled the induction experience as being more pleasant (P=0.03) than those who did not receive midazolam. These results indicate that midazolam may be given up to 10 minutes prior to propofol and still achieve a substantial dose reduction.
Co-induction of anaesthesia with propofol and midazolam has become a popular technique. Use of the synergism between midazolam and propofol may offer a better balance between desired and adverse effects providing a better overall clinical outcome 1 . An important element in achieving this balance is the timing of administration of drugs so that their peak effects coincide 2 .
Although the pharmacokinetics and pharmacodynamics of propofol and midazolam, as well as their combination [3] [4] [5] , have been the subject of numerous reports, there has been no study looking specifically at the timing of midazolam before propofol to achieve a maximal reduction in propofol dose in a clinical setting.
The purpose of this study was to determine how long after midazolam the propofol should be given to achieve maximal dose reduction. This was done by determining the ED50 of propofol administered at various time intervals up to 10 minutes following a bolus dose of midazolam. A maximal interval of 10 minutes was chosen because it was considered that longer intervals would be unacceptable in clinical practice. The bolus dose size of midazolam chosen was 3 mg for all patients. We wanted to use a dose which was near the high end of the range commonly used in clinical practice, so as to be able to demonstrate a significant reduction in propofol requirement without the need for very large patient numbers. A 5 mg dose of midazolam prior to induction has been reported to delay recovery from anaesthesia 6 , so we elected to limit the dose to 3 mg.
MATERIALS AND METHODS
This study was approved by the Clinical Investigations Committee (Ethics Committee) of Flinders Medical Centre. ASA 1 or 2 females scheduled for gynaecological surgery, aged 18 to 45 years and weighing 40 to 75 kg were eligible for the study. Patients with any contraindication to midazolam or propofol and those prescribed any premedication were excluded. Patients who provided written informed consent were assigned by a computer-generated randomization list to treatment Groups 1 to 6. Patients in Group 1 received no midazolam, while those in Groups 2 to 6 received midazolam 3 mg IV 1, 2, 4, 6 or 10 minutes respectively, prior to propofol administration. No drug other than the study medications was administered during the induction procedure. In order to maintain blindness, two coded syringes were provided for each patient. For patients in Group 1, two syringes containing saline 3 ml were given at different times randomly selected from 1, 2, 4, 6 or 10 minutes prior to propofol. For patients in Groups 2 to 6, one syringe containing midazolam 3 mg in 3 ml was administered at the appropriate time, while the other syringe containing saline 3 ml was given at a different randomly selected time.
The contents of the two coded syringes were administered at the designated times prior to propofol. The dose of propofol, determined as described below, was administered over 10 seconds and flushed in with 5 ml of saline. Two minutes after propofol administration, pressure was applied to the pulp of the index finger for up to 4 seconds by means of a device similar to that described by Johnson and Watson 7 . This consisted of a 20 ml glass syringe filled with 20 ml of air and capped with a stainless steel cap having a flat circular surface of diameter 4 mm. The cap was placed against the finger and the plunger of the syringe was depressed until the air inside was reduced to a volume of 12.5 ml. Patients not responding to the pressure were deemed to have lost consciousness. When necessary, additional propofol was given prior to surgery.
After patients had returned to the ward, they were visited by an investigator and asked how they felt about the procedure used for putting them to sleep, using a five-point scale ranging from "very unpleasant" to "very pleasant", with the additional response category, "can't remember anything about it". Patients were also questioned about recollection of specific events during induction, including whether they could recall any injection being painful.
The up-and-down method 8 was used to determine the ED50 of propofol within each treatment group. Using the up-and-down method, the first patient in a group is given a dose of the drug thought to be near the ED50. If the first patient loses consciousness, the second is given a smaller dose; if the first patient does not lose consciousness, the second is given a larger dose. As the procedure is repeated with further patients, the mean of the doses administered tends toward the ED50. We chose the starting dose for each group to be 1.5 mg/kg lean tissue mass (LTM) 9 . LTM was calculated by the following formula 10 :
where W is weight in kg, H is height in cm and G is girth at the umbilicus in cm. The dose increment/decrement between consecutive patients should be small if inter-individual variation in response to the drug is small, and large if interindividual variation is large. Variation among individuals may be described by the standard deviation of individual tolerances. The tolerance of an individual is the smallest dose of drug which will elicit a response (here loss of consciousness) in that individual. The standard deviation of tolerances may be estimated from the slope of probit doseresponse curves. Based on published data 3,5,11 , we estimated the standard deviation of individual tolerances to propofol to be 0.25 when dose is expressed as its natural logarithm. We chose the dose increment/decrement to be equal to two-thirds of this value. This led to a possible series of propofol doses of … 0.90, 1.07, 1.27, 1.50, 1.78, 2.11, … 2.50 mg/kg LTM.
ED50s (on a logarithmic scale) and their variances were calculated as described by Choi 12 . Two null hypotheses were tested. The null hypothesis that prior midazolam had no influence on propofol ED50 was tested by one-factor analysis of variance (ANOVA) using a linear contrast comparing the five midazolam groups to Group 1. The null hypothesis that timing of midazolam administration had no influence on propofol ED50 was tested by conducting a one-factor ANOVA comparing Groups 2 to 6 only. If the latter null hypothesis was rejected (P<0.05), then each of the midazolam groups was compared separately to Group 1.
The same hypotheses were tested for ordinal data (e.g., patients' ratings of how they felt about the induction experience) using Kruskal Wallis tests, and for dichotomous data (e.g., recall of pain on injection) by Chi-square tests.
It was estimated that 20 subjects per group would provide approximately 85% power to detect a 25% reduction in propofol ED50 in any of the midazolam groups, compared to Group 1. Using the method of Choi 12 the estimate of the ED50 is taken as the mean of the turning points, excluding the first. "Turning points" are where two consecutive patients respond differently. A string of like responses at the end of the run contributes no additional information. We therefore retained the option of including more than 20 patients in each group, if necessary to reach a new turning point.
RESULTS
One hundred and twenty-four patients completed the study. Groups were similar with respect to demographic variables (Table 1) . No patient suffered any significant adverse effects due to the study medication and none had a clinically significant fall in blood pressure during induction of anaesthesia. Figure 1 shows the profile of responses for patients in Group 1. Thus, patient number 1, who received 1.5 mg/kg LTM propofol, did not lose consciousness and so patient number 2 received the next higher dose, 1.78 mg/kg LTM, and did lose consciousness. A "turning point" is defined as the dose midway between those received by two consecutive patients with unlike responses. The first (w1) and last (w13) turning points in this series are shown on the graph.
Prior administration of midazolam resulted in a significant (P=0.001) reduction in propofol ED50. Compared to Group 1, ED50 was reduced by (per cent reduction, 95% confidence limits): 55 (24, 73), 56 (27, 73), 57 (27, 74), 33 (-12, 60) and 66 (43, 80) in Groups 2 to 6, respectively. Within Groups 2 to 6, propofol ED50 did not vary significantly (P=0.14) ( Figure 2 ). Examination of Figure 2 suggests that the timing of midazolam has a biphasic effect on propofol ED50, with an initial reduction up to 4 minutes, and a second, greater reduction at 10 minutes. This unexpected observation was examined by constructing a post hoc linear contrast to compare the ED50s in Groups 5 and 6. There was a significant (P=0.009) difference.
One patient in Group 5 was discharged earlier than expected and no follow-up assessment was made. Each study patient received three injections (saline, midazolam or saline, propofol) up to the time of induction. Patients who did not receive midazolam (Group 1) were more likely to recall an injection being painful (P<0.001) ( Figure 3 ) and could recall more of the injections which were given (P<0.001) (Figure 4 ). There was no significant difference (P=0.06) in number of injections recalled among the five groups which received midazolam. Group 1 (no midazolam) rated the experience of induction as being less pleasant than did patients in Groups 2 to 6 (P=0.03), ( Figure 5 ). There was no significant difference in rating between the midazolam treated groups (P=0.53). A total of 14 patients stated they had no recall of induction (n=1, 1, 3, 2, 1, 6 in Groups 1 to 6 respectively) and were excluded from this part of the analysis. 
DISCUSSION
Prior administration of midazolam resulted in a significant reduction in the ED50 of propofol for induction of anaesthesia. Reductions in propofol dose to less than 50% of that required in the absence of midazolam were achieved for up to 4 minutes following midazolam; at 10 minutes following midazolam only 34% of the usual propofol dose was required. This is in agreement with results of previous studies 3, 5 . Midazolam is reported to exhibit a lag time of 90 seconds to clinical effect, with a peak effect occurring between 3 and 5 minutes after a bolus dose, while propofol has a quicker onset with a peak effect occurring after one to two minutes 1, 4 . Based on this, it would be expected that the optimal timing of propofol would be between one and three minutes after midazolam. While this is supported by our results, we also found that delays of up to 10 minutes are still associated with good clinical effect.
While we found no statistically significant differences in propofol ED50 when the five groups which received midazolam were compared by ANOVA, there was an indication that the propofol-sparing effect of midazolam was less when it was given six minutes prior to propofol. However, the lowest propofol ED50 occurred in the group which received midazolam 10 minutes beforehand, and this was highly significantly lower than in the six-minute group, which raises the possibility that midazolam had a biphasic effect. The significance levels of such statistical tests carried out after viewing the data should be interpreted with caution. Therefore, in the absence of corroboration by other studies, we do not consider that the present results should be interpreted as demonstrating a biphasic effect of midazolam. An alternative explanation is that the seemingly high ED50 of propofol when given six minutes after midazolam ( Figure 2) is a chance event.
In our study, midazolam and saline were provided in coded syringes to blind the investigator and patient to the nature of the substance being administered. Due to the marked pharmacological effects of midazolam, there is a possibility that blinding was not maintained. However, in a number of cases the investigator performing the induction believed that midazolam had been administered, though it was later found that the patient had received only saline. This is probably due to sedation induced by the placebo effect of the IV injection, which might be particularly pronounced in an anxious patient prior to surgery. Consequently, the risk of unblinding was not as great as might be expected.
In our study the patient groups which received midazolam rated the experience of induction of anaesthesia as more pleasant than those who did not receive midazolam. These groups had less recall of events surrounding induction, including painful injection. It may be that many patients do not want to recall these events, and so the amnesic effect of midazolam may contribute to patient satisfaction. This alone warrants wider consideration of the technique of co-induction.
